BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 10403472)

  • 1. Phase III randomized trials of docetaxel in patients with metastatic breast cancer.
    Crown J
    Semin Oncol; 1999 Jun; 26(3 Suppl 8):33-8. PubMed ID: 10403472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III studies of single-agent docetaxel in patients with metastatic breast cancer who have progressed despite previous chemotherapy regimens: preliminary results.
    Nabholtz JM; Crown J
    Semin Oncol; 1998 Dec; 25(6 Suppl 13):4-9. PubMed ID: 9865685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-agent docetaxel (Taxotere) in randomized phase III trials.
    Burris HA
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):1-6. PubMed ID: 10426452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer.
    Nabholtz JM; Thuerlimann B; Bezwoda WR; Melnychuk D; Deschênes L; Douma J; Vandenberg TA; Rapoport B; Rosso R; Trillet-Lenoir V; Drbal J; Aapro MS; Alaki M; Murawsky M; Riva A
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):25-30. PubMed ID: 9364538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of the efficacy and safety of docetaxel as monotherapy in metastatic breast cancer.
    Crown J
    Semin Oncol; 1999 Feb; 26(1 Suppl 3):5-9. PubMed ID: 10203264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel (Taxotere) in combination with anthracyclines in the treatment of breast cancer.
    Nabholtz JM; North S; Smylie M; Mackey J; Au HJ; Au R; Morrish D; Salter E; Tonkin K
    Semin Oncol; 2000 Apr; 27(2 Suppl 3):11-8. PubMed ID: 10810933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel versus doxorubicin in patients with metastatic breast cancer who have failed alkylating chemotherapy: a preliminary report of the randomized phase III trial. 303 Study Group.
    Aapro M
    Semin Oncol; 1998 Oct; 25(5 Suppl 12):7-11. PubMed ID: 9865705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy.
    Chan S
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):19-24. PubMed ID: 9364537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compilation of phase I and II trial data of docetaxel and doxorubicin in the treatment of advanced breast cancer and other malignancies.
    Sparano JA
    Semin Oncol; 1998 Dec; 25(6 Suppl 13):10-5. PubMed ID: 9865686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The current status of docetaxel for metastatic breast cancer.
    Esteva FJ
    Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):17-26. PubMed ID: 12108894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I-II studies of docetaxel as a single agent in the treatment of metastatic breast cancer.
    Trudeau ME
    Semin Oncol; 1999 Jun; 26(3 Suppl 8):21-6. PubMed ID: 10403470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer.
    Costa SD; von Minckwitz G; Raab G; Blohmer JU; Dresel V; Eidtmann H; Hilfrich J; Jackisch C; Merkle E; Gademann G; Kaufmann M
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):24-31. PubMed ID: 10426456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution in the treatment of advanced breast cancer.
    Crown J
    Semin Oncol; 1998 Oct; 25(5 Suppl 12):12-7. PubMed ID: 9865706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docetaxel in combination chemotherapy for metastatic breast cancer.
    Khayat D; Antoine E
    Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-19-S13-26. PubMed ID: 9335513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel (Taxotere) plus doxorubicin-based combinations: the evidence of activity in breast cancer.
    Nabholtz JM
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):7-13. PubMed ID: 10426453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docetaxel (Taxotere) in combination: a step forward.
    Burris HA; Fields S; Peacock N
    Semin Oncol; 1995 Dec; 22(6 Suppl 13):35-40. PubMed ID: 8604452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel and anthracycline polychemotherapy in the treatment of breast cancer.
    Nabholtz JM; Smylie M; Mackey J; Au HJ; Tonkin K; Au R; Morrish D; Salter E
    Semin Oncol; 1999 Jun; 26(3 Suppl 8):47-52. PubMed ID: 10403474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel (Taxotere): an effective agent in the management of second-line breast cancer.
    van Oosterom AT
    Semin Oncol; 1995 Dec; 22(6 Suppl 13):22-8. PubMed ID: 8604449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging role of docetaxel (Taxotere) in the adjuvant therapy of breast cancer.
    Ravdin PM
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):20-3. PubMed ID: 10426455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.
    Chan S; Friedrichs K; Noel D; Pintér T; Van Belle S; Vorobiof D; Duarte R; Gil Gil M; Bodrogi I; Murray E; Yelle L; von Minckwitz G; Korec S; Simmonds P; Buzzi F; González Mancha R; Richardson G; Walpole E; Ronzoni M; Murawsky M; Alakl M; Riva A; Crown J;
    J Clin Oncol; 1999 Aug; 17(8):2341-54. PubMed ID: 10561296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.